The characteristics of patients with mycobacterium tuberculosis blood stream infections in Beijing, China: a retrospective study by unknown
RESEARCH ARTICLE Open Access
The characteristics of patients with
mycobacterium tuberculosis blood
stream infections in Beijing, China:
a retrospective study
Xiaoqing Liu1,2*†, Sainan Bian1†, Yueqiu Zhang1, Lifan Zhang1,2, Qiwen Yang3, Peng Wang3, Yingchun Xu3,
Xiaochun Shi1, Yao Zhang2 and Roy F. Chemaly4
Abstract
Background: Published information regarding the clinical characteristics, laboratory findings, and outcomes of
patients with Mycobacterium tuberculosis (MTB) blood stream infection (BSI) is limited. We aimed in this study
to evaluate the clinical characteristics, laboratory evaluation, and outcomes of patients with MTB BSI.
Methods: All patients diagnosed with MTB BSI at Peking Union Medical College Hospital between January 2008
and May 2014 were identified by examining the electronic database listing results of all blood cultures. Data on
demographics, clinical characteristics, laboratory manifestations, management, and outcomes were abstracted
from medical records.
Results: Six thousand nine hundred seventy-four patients had mycobacterial blood cultures during the study
period. Of 48 patients (0.7%) with MTB BSI, 26 patients (54%) were considered to be immunocompromised (refers
to a person who has a significantly impaired immune system). This was due to human immunodeficiency virus
(HIV) infection (n = 2 of 48 tested), receiving steroids (n = 17, including 16 with rheumatic diseases and one with
myasthenia gravis), malignancy (n = 3), diabetes mellitus (n = 3), and renal transplantation (n = 1). The main clinical
manifestations were fever (100%, with a median of 40 °C), weight loss (48%) and cough with sputum production
(46%). Most patients had one or more organs involved (81%). The median time from onset of fever to diagnosis
was 8 weeks (IQR 5 ~ 14). Six patients died within 1 week after diagnosis. Of the 17 patients completing treatment,
14 patients (82%) recovered without major complications and they had a shorter time interval between onsets of
symptoms to treatment compared to those died of TB.
Conclusions: In this group of patients with MTB BSI, fever and multiple organs involvement were common, the
outcome was poor and timely diagnosis and treatment might favor outcome.
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Background
Developing countries like China face a challenging com-
bination of an expanding epidemic of human immuno-
deficiency virus (HIV) infection, cancer, and persistently
high prevalence of tuberculosis (TB) [1]. These combina-
tions may place a growing proportion of its population at
risk for severe forms of Mycobacterium tuberculosis
(MTB) infections, including dissemination and MTB
blood stream infection (BSI) (refers to those with positive
MTB blood cultures) with subsequent poor outcomes.
Hematogenous, disseminated, or miliary tuberculosis
has been used exchangeably in the literature describing
in most instances a lymphohematogenous spread of
MTB. Miliary tuberculosis accounts for about 1–2% of
all cases and about 8% of all forms of extrapulmonary
TB in immunocompetent individuals [1].
Reports on MTB BSI are scarce with most pub-
lished data emerging from the HIV infected patients
[2, 3]. Few studies report MTB BSI among a general
population [4, 5]. With the use of liquid culture
methods in recent years, it became possible to isolate
MTB from blood culture bottles. In a prospective
cohort of 368 HIV-infected patients hospitalized with
severe sepsis [3], 86 patients (23%) had MTB BSI,
and the 30-day mortality of patients with or without
MTB BSI was 53.2 and 30.7%, respectively. In a study
enrolling 238 consecutive febrile adult patients, 173
(73%) were HIV-positive and 67 (28%) had BSI, show-
ing that MTB ranked second at 19% as etiology of
bloodstream infections [4]. In another study of 57
patients (55 were HIV positive) with MTB BSI, 42%
died within 1 month of hospitalization [5].
Because of the high mortality associated with MTB BSI,
we aimed in this study to better understand the clinical
and laboratory manifestations and the impact of this infec-
tion among patients who were admitted to our institution,
a major national referral hospital in Beijing, China.
Methods
Study population
All patients diagnosed with MTB BSI at Peking Union
Medical College Hospital between January 2008 and
May 2014 were identified by examining the electronic
database listing results of all blood cultures. Data on
demographics, clinical characteristics, underlying dis-
eases, laboratory manifestations, management, and out-
comes were abstracted from medical records.
Criteria for determining who gets mycobacterial blood
culture was fever last for more than 3 weeks,
temperature above 38.3 °C, and still not being diagnosed
after complete history consultation, physical examin-
ation, and routine laboratory examinations for 1 week. If
the patient had fever in hospital and was suspected of
bacteremia, and if the patient was immunocompromised,
the criteria might be a little wider which was determined
by the treating clinicians.
Immunocompromised refers to a person who has a sig-
nificantly impaired immune system according to the Na-
tional Institute for Health and Care Excellence (NICE)
guideline. For instance, this may be because of prolonged
corticosteroid use, tumor necrosis factor-alpha antago-
nists, antirejection therapy, immunosuppression-causing
medication or comorbid states that affect the immune
system, for example, HIV, chronic renal disease, many
haematological and solid cancers, and diabetes [6].
Laboratory diagnosis
The laboratory diagnosis of MTB BSI was based on the
following: Peripheral blood cultures were collected and
inoculated into a liquid culture method (Bact Alert MP,
BioMerieux) between 2008 and 2010 and BD MGIT960
(BD) after 2010. Recovery of mycobacteria confirmed by
acid-fast stain (Ziehl-Neelsen stain and Auramine-
rhodamine stain) according to “Manual of Clinical
Microbiology” [7]. And then Tuberculosis Antigen
Colloidal Gold Diagnostic Kit (Kabelykit. Protocol is avail-
able at http://www.hgb.com.cn/cp1/show/id/44.html) and
gene chip [8] are used to identify the type of Mycobacter-
ium species according to the manufacturer’s instructions.
The direct smear on clinical specimens is done by
Auramine-rhodamine stain and Ziehl-Neelsen stain at
the same time following the standard in “Manual of
Clinical Microbiology” [7].
Four milliliters of peripheral blood were collected from
each patient and was performed within six hours after
collection by laboratory personnel blinded to patients’
clinical data. In the T-SPOT.TB test, AIM-V (GIBCOT-
MAIM V Medium liquid, Invitrogen, US) was used as
negative control, phytohemagglutinin (PHA) as positive
control, and early-secreted antigenic target 6-kDa pro-
tein (ESAT-6) and culture filtrate protein 10 (CFP-10) as
specific antigens, respectively. Peripheral blood mono-
nuclear cells (PBMCs) were separated by Ficoil-Hypaque
gradient centrifugation and obtained (2.5 × 105per well)
on a plate (Oxford Immunotec, Abingdon, UK) that was
pre-coated with an antibody against interferon-γ. After
incubation for 16 to 18 h at 37 °C in 5% carbon dioxide,
wells were washed and developed with a conjugate used
and an enzyme substrate against the antibody. The num-
ber of spot-forming cells (SFCs) representing an antigen-
specific T cell that secreted interferon-γ were counted
with an automated ELISPOT reader (AID-ispot, Strass-
berg, Germany). A positive result of T-SPOT.TB on
PBMCs was defined as six or more SFCs in the target
well and had twice the number of spots than the
negative control well. In addition, the background
number of spots in the negative control well should
be less than ten SFCs [9].
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Statistical analysis
We used Kolmogorov-Smirnov test to check if the vari-
ables followed normal distribution. Measurement data of
normal distribution was expressed by mean ± standard
deviation (SD), and measurement data of non-normal
distribution was expressed by median and interquartile
range (IQR). Enumeration data was expressed by per-
centage. The Pearson’s Chi-square test was used to com-
pare proportions between groups. Results with a 2-sided
P value <0.05 were considered statistically significant.
Statistical analysis was performed by SPSS 16.0 (SPSS
Inc, Chicago, IL, USA).
Results
We searched the electronic database in the clinical
microbiology laboratory at Peking Union Medical
College Hospital, and found 56 reports of positive Myco-
bacterium species from peripheral blood samples be-
tween January 2008 and May 2014. Then we excluded
eight cases of non-Mycobacterium tuberculosis (NTM),
48 patients were MTB BSI.
General conditions
Patients‘characteristics are summarized in Table 1.
Among the 48 patients, 25 patients (52%) were males
and the median age was 44 years (IQR 26 ~ 57). In
addition to the MTB BSI, 26 patients (54%) had pulmon-
ary tuberculosis, among these patients 13 (50%) had
positive sputum smear for AFB, six (23%) had positive
sputum culture for MTB (four patients had smear and
culture positive), and 11 (42%) had radiological findings
suggestive of pulmonary tuberculosis with negative
smear and cultures from sputum. Other organ(s) in-
volvement included the central nervous system (CNS) in
seven (14%) patients, serositis including pleuritis, peri-
tonitis, and pericarditis in five (10%), liver in five (10%),
osteo-articular joints in four (8%), skin and soft tissue in
three (6%), lymphatic system in three (6%), intestinal
tract in two (4%), and spleen in two (4%). Most of the
patients (26, 54%) were immunocompromised due to
their underlying conditions and/or being on immuno-
suppressive therapy and only two patients (4%) were
positive for HIV with a CD4 count of 25/mm3 and 60/
mm3 each (Table 1).
Clinical manifestations
The most common clinical manifestation was fever with
a median time from fever to diagnosis of MTB BSI of
8 weeks (IQR 5 ~ 14). The median peak temperature was
40 °C, (IQR 39.5 ~ 40.1). Other clinical manifestations
included cough with sputum production in 22 patients
(46%), reported weight loss in 23 patients (48%), and
night sweats in seven patients (15%). In addition, 12
patients (25%) had enlarged lymphatic nodes, 17 (35%)
had hepatomegaly, and 27 (56%) had splenomegaly.
Laboratory examinations
The laboratory findings are depicted in Table 2. Among
the 41 patients who had a T-SPOT.TB assay done, 28
(68%) were positive with a median spots counts of 556
SFC/106PBMC, (IQR 112 ~ 1704) (Table 3). The sensitiv-
ity of the T-SPOT.TB assay in patients with CD4 count >
200/mm3 was 100% compared to 57% in patients with
CD4 counts < 200/mm3 (P = 0.018). When we looked at
the absolute lymphocytes count (ALC), the sensitivity of
the T-SPOT.TB assay was much higher in patients with
ALC > 500/mm3 when compared to patients with ALC <
500/mm3 (85% vs. 52%, respectively, P = 0.025) (Table 4).
Treatment and outcome
Data on therapy was available for 39 patients as the
remainder nine patients were transferred to other
facilities before any therapy was initiated. All the
patients received at least three out of the four drugs
of the standard regimen (Isoniazid 0.3 g/d, Rifampin
0.45 g/d, Pyrazinamide 0.75 g/d, and Ethambutol
Table 1 Demographics and underlying conditions of the 48
patients with MTB BSI






















HIV Human immunodeficiency virus, SLE Systemic lupus erythematosus, SS
Sjogren Syndrome, RA Rheumatoid arthritis, DM Dermatomyositis, MCTD Mixed
connective tissue diseases, CTD Connective tissue diseases
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0.75 g/d) and in combination with a quinolone in 27
patients (Moxifloxacin 0.4 g/d (n = 10), and Levofloxa-
cin 0.5 g/d (n = 17)).
In total 25 patients were lost to follow-up (Nine pa-
tients were transferred to other facilities before any ther-
apy was initiated and 16 were lost to follow-up prior to
completing treatment). 14 (36%) recovered well without
major complications, and one patient with tuberculous
meningoencephalitis recovered but with subsequent sei-
zures with a median duration of 12 months of treatment
(range 6–30 months). The remaining eight patients
(20.5%) died at a median of 2 days (range: 2 to 150 days)
from diagnosis (seven died of TB, and one of gastric
perforation).
Among the 26 immnocompromised patients, six
patients (23%) died of TB, while among 22 immunocom-
petent patients, one patient (5%) died of TB (P = 0.07),
they all had poor outcomes.
With a comparison of the 15 patients recovered with
those eight patients died, median time from onset of
symptoms to receiving treatment was 30 days (IQR 17-
60) and 55 days (IQR 37-96), respectively (P = 0.023).
Discussion
We report a large series of patients with MTB BSI. Our
data showed that patients with MTB BSI usually have
multiple organs involvement with varied serious compli-
cations. In addition, the time to diagnosis could be long
and the outcome was generally poor. On the other hand,
we found that sensitivity of T-SPOT.TB assay was high
mainly in patients with CD4 count above 200/mm3.
Tuberculosis remains one of the most challenging
communicable diseases in the world. In 2013, an esti-
mated 9.0 million individuals developed TB and 1.5
million died. China alone accounted for 11% of the total
cases worldwide [10]. Although pulmonary tuberculosis
is the form given the most attention for its public health
relevance, other forms of TB, including MTB BSI are
also important, particularly when more people are be-
coming immunocompromised due to cancers, or other
chronic diseases. Interestingly, in one study conducted
in Malawi showed that MTB ranked second at 19% as
etiology of bloodstream infections [4]. MTB BSI was
more likely to occur in HIV-positive than in HIV-
negative patients (13/173 vs. 0/65; P < 0.05) [4]. MTB
BSI in patients with HIV infection or other immuno-
suppressive diseases resulted in death in most patients
[2, 3, 11]. Whether early and prompt diagnosis and
treatment would have impact on the overall prognosis
should be determined in future studies.
Hematogenous, disseminated, or miliary tuberculosis
has been used exchangeably in the literature describing
in most instances a lymphohematogenous spread of
MTB. Miliary tuberculosis accounts for about 1–2% of
all cases and about 8% of all forms of extrapulmonary
TB in immunocompetent individuals. These forms of
infections are more frequently encountered in immuno-
compromised patients [1, 12, 13] as seen in our study
Table 2 Laboratory findings on 48 patients with MTB BSI
Characteristic Value (n = 48) (n.%)
Leukocytopenia 24 (50)
Anemia 38 (79)
Low platelet count 28 (58)
High leukocyte count 17 (35)
Leukocytes, ×109/L [median (IQR)] 4.58, (1.94 ~ 13.67)
Hemoglobin, g/L[mean ± SD] 88 ± 32
Platelets, ×109/L[median (IQR)] 74, (25 ~ 213)
Lymphocytes, ×109/L [median (IQR)] 0.35, (0.20 ~ 0.74)
Increased ESR 34/45(76)
Increased hsCRP 34/36 (94)
ESR, mm/h [median (IQR)] 69, (IQR 27 ~ 103)
hsCRP, mg/L [median (IQR)] 121.5, (IQR 56.4 ~ 176.5)
CD4+ count, /mm3, [median (IQR)] (n = 27) 115, (IQR 77-187)
CD8+ count, /mm3, [median (IQR)] (n = 27) 168, (IQR 78-246)
Time from MTB culture to a positive result,
d[median (IQR)]
27, (IQR 21 ~ 33)
ESR Erythrocyte sedimentation rate, hsCRP Hypersensitive C reactive protein
Leukocytopenia: <4 × 109/L; Anemia: Male < 120 g/L and female < 110 g/L; Low
platelet count: <100 × 109/L; High leukocyte count: >10 × 109/L; Increased ESR:
Male > 15 mm/h and female > 20 mm/h; Increased hsCRP: >3 mg/L
Table 3 Results of the T-SPOT.TB assay on 41 patients
T-SPOT.TB (SFC/106PBMC) MTB
Positive results 28/41 (68%)
Total 556 (IQR 112 ~ 1704)
ESAT-6 116 (IQR 34 ~ 242)
CFP-10 100 (IQR 40 ~ 722)
Negative results 13/41 (32%)
ESAT-6: 6 kDa, specific antigens encoded in the RD1 region; CFP-10: 10 kDa,
specific antigens encoded in the RD1 region






CD4 < 100/mm3(n = 10) 4 (40) 6 (60)
CD4 100-200/mm3(n = 11) 8 (73) 3 (27)
CD4 > 200/mm3(n = 6) 6 (100) 0 (0)
P value 0.018
ALC < 500/mm3(n = 21) 11 (52) 10 (48)
ALC > 500/mm3(n = 20) 17 (85) 3 (15)
P value 0.025
ALC Absolute lymphocyte count
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where the majority of patients (54%) had an underlying
immunosuppression. We hypothesize that initial expos-
ure occurs through the respiratory route that may or
may not result in pulmonary TB at later stages
dependent most probably on the inoculum effect and
the virulence of MTB in addition to the immune status
of the host. Dissemination could occur through the
blood and seed many organs, oxygen rich organs in
particular, such as the brain, bones, lungs, and spine.
Not surprisingly, the most common organ involved
in patients with MTB BSI was the lungs (54%). The
radiological manifestations were atypical in early
stages and included, either normal findings, or
ground-glass opacities, and progressed to miliary
nodular patterns at later stages. A retrospective study
of 2016 cases with culture-proven TB [14] showed
that miliary and pneumonic radiographic patterns
were risk factors for fatal outcomes. In addition, pre-
vious study [1] supported that there is an association
between the occurrence of miliary MTB and a
massive lymphohaematogenous dissemination of the
pathogen from a pulmonary or extrapulmonary source
resulting in embolization of the vascular beds of vari-
ous organs. Subsequently, cerebral, hepatic or splenic
involvement with MTB was most probably preceded
by the hematogenous spread of this pathogen.
Whether early diagnosis of MTB BSI in high endemic
countries, like China, may prevent seeding of MTB in
different organs with prompt therapy should be deter-
mined in future studies.
We also evaluated the performance of the T-SPOT.TB
assay among patients with MTB BSI. The overall sensi-
tivity was 68%, lower than what is reported in the litera-
ture [6, 15]. Although this assay performed well in
patients with underlying immunosuppressive conditions,
the combination of disseminated TB and the immuno-
suppressive status of some of our patients with low CD4
counts, may have contributed to this low sensitivity for
the diagnosis of active TB. Similar results was found in
another study that the sensitivity of the TB ELISPOT
assay decreased from 97 to 81% when patients were
stratified according to absolute lymphocytes count
(ALC) above 1000/ml or less than 500/ml, respectively
(P = 0.007) [16].
As the only confirmatory test available, the turnaround
time for culture is long, which makes the diagnosis chal-
lenging and delayed. Median culture time of MTB was
26.6 days in our study which was similar to other report
[17]. On another hand, it is recommended more than
one blood specimen to be collected to increase the diag-
nostic yield for cultures [17]. We may apply the new
method of GeneXpert MTB/RIF in the future which can
detect MTB in 2 h with a good sensitivity and specificity
[18]. It allows rapid laboratory confirmation of MTB and
that empiric therapy is warranted pending laboratory
confirmation, especially when disseminated TB is likely.
There are some limitations in our study. This is a
retrospective study from a single referral tertiary care
hospital caring most for complicated and serious dis-
eases in China. And some patients were lost to follow-
up. So our findings may not be generalizable to other
patients in other centers.
Conclusions
In summary, MTB BSI is a serious complication even
among non-immunosuppressed patients. Multiple
organs involvement is common and is associated with
poor outcomes. Rapid diagnosis and prompt therapy
may favorably impact outcomes.
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